• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The emerging role of incretins and twincretins.

作者信息

Chow Elaine, Chan Juliana C N

机构信息

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.

Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.

出版信息

Nat Rev Endocrinol. 2022 Feb;18(2):73-74. doi: 10.1038/s41574-021-00607-w.

DOI:10.1038/s41574-021-00607-w
PMID:34873288
Abstract
摘要

相似文献

1
The emerging role of incretins and twincretins.肠促胰岛素和双促胰岛素的新作用
Nat Rev Endocrinol. 2022 Feb;18(2):73-74. doi: 10.1038/s41574-021-00607-w.
2
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.基于双重肠促胰岛素受体激活的糖尿病和肥胖治疗：“双激素”。
Diabetes Obes Metab. 2016 Sep;18(9):847-54. doi: 10.1111/dom.12685. Epub 2016 Jun 7.
3
Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension.肠促胰岛素对血压的影响：高血压合并 2 型糖尿病的有前途的治疗方法。
J Diabetes. 2012 Mar;4(1):22-9. doi: 10.1111/j.1753-0407.2011.00167.x.
4
Twincretins: Emerging therapies for diabetes and obesity.双促胰岛素：糖尿病和肥胖症的新兴疗法。
J Pak Med Assoc. 2023 Jan;73(1):2-3. doi: 10.47391/JPMA.01-23.
5
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.肠促胰岛素：从概念到其在2型糖尿病治疗中的应用。A部分：肠促胰岛素：概念与生理功能。
Diabetes Metab. 2008 Dec;34(6 Pt 1):550-9. doi: 10.1016/j.diabet.2008.09.001. Epub 2008 Nov 25.
6
Targeting the incretin system in type 2 diabetes mellitus.针对2型糖尿病中的肠促胰岛素系统
Mt Sinai J Med. 2009 Jun;76(3):244-56. doi: 10.1002/msj.20112.
7
[Incretins have changed and continue to change treatment strategy for type 2 diabetes].
Vnitr Lek. 2011 Nov;57(11):916-8.
8
[The physiology of incretins].[肠促胰岛素的生理学]
Orv Hetil. 2011 Nov 27;152(48):1922-30. doi: 10.1556/OH.2011.29237.
9
[The concept of incretins and the physiological roles of incretins].[肠促胰岛素的概念及肠促胰岛素的生理作用]
Nihon Rinsho. 2011 May;69(5):761-9.
10
Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.评估 2 型糖尿病合并肠促胰岛素患者骨折风险：一项更新的荟萃分析。
Endokrynol Pol. 2021;72(4):319-328. doi: 10.5603/EP.a2021.0031. Epub 2021 May 19.

引用本文的文献

1
MASLD development: From molecular pathogenesis toward therapeutic strategies.代谢相关脂肪性肝病的发展：从分子发病机制到治疗策略
Chin Med J (Engl). 2025 Aug 5;138(15):1807-1824. doi: 10.1097/CM9.0000000000003629. Epub 2025 Jul 10.
2
Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy.将肥胖与2型糖尿病联系起来的内分泌和代谢机制：对靶向治疗的启示。
Healthcare (Basel). 2025 Jun 16;13(12):1437. doi: 10.3390/healthcare13121437.
3
Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism.

本文引用的文献

1
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.双重葡萄糖依赖性胰岛素促分泌多肽和胰高血糖素样肽-1 受体激动剂替西帕肽可改善 2 型糖尿病患者的心血管风险生物标志物：一项事后分析。
Diabetes Obes Metab. 2022 Jan;24(1):148-153. doi: 10.1111/dom.14553. Epub 2021 Oct 11.
2
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.在外源性合成人胃抑制多肽和胰高血糖素样肽-1-(7-36)酰胺以接近生理促胰岛素激素和葡萄糖浓度输注时的相加促胰岛素作用。
J Clin Endocrinol Metab. 1993 Apr;76(4):912-7. doi: 10.1210/jcem.76.4.8473405.
在人胰岛微组织中，促炎细胞因子诱导的α细胞损伤可通过双重肠促胰岛素受体激动作用得到部分恢复。
Diabetologia. 2025 May 15. doi: 10.1007/s00125-025-06425-3.
4
Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.基于胰高血糖素样肽-1的疗法在2型糖尿病和肥胖症管理中的分子药理学
Integr Pharm Res Pract. 2025 Apr 6;14:59-72. doi: 10.2147/IPRP.S503501. eCollection 2025.
5
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.胰高血糖素样肽 1、葡萄糖依赖性胰岛素促分泌多肽和胰高血糖素受体激动剂在代谢功能障碍相关脂肪性肝病中的作用：新肝病命名中的新型药物。
Int J Mol Sci. 2024 Mar 29;25(7):3832. doi: 10.3390/ijms25073832.
6
Type 2 Diabetes and the Microbiome.2型糖尿病与微生物群
J Endocr Soc. 2022 Nov 30;7(2):bvac184. doi: 10.1210/jendso/bvac184. eCollection 2022 Dec 15.
7
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.替尔泊肽：糖尿病和肥胖双重靶向治疗的新时代：一篇迷你综述。
Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315.